Dovitinib (dilactic acid)
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis[1].
Product Specifications
CAS Number
852433-84-2
Product Name Alternative
CHIR-258 (dilactic acid) ; TKI258 (dilactic acid)
UNSPSC
12352005
Target
VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dovitinib-dilactic-acid.html
Solubility
DMSO : ≥ 30 mg/mL
Smiles
CC(O)C(O)=O.CC(O)C(O)=O.O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3
Molecular Formula
C27H33FN6O7
Molecular Weight
572.59
References & Citations
[1]Zhu, S., et al. The Chemical Development of CHIR-258. CHIMIA International Journal for Chemistry, 60 (9), 584–592.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog